Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

Predictive Modeling of Venetoclax/Azacitidine Response in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ASA. SrivastavaUniversity of HelsinkiBTBahar TercanInstitute for Systems BiologyDGDavid L. GibbsInstitute for Systems Biology

Discussion

Loading...

Member takes

Implication

Predictive modeling demonstrates cytokine profiling can accurately forecast treatment response in AML, suggesting personalized therapy options.

Key Points

  • The aim is to develop predictive models for patient response to venetoclax and azacitidine treatments in acute myeloid leukemia using cytokine and clinical data.
  • Cytokine profiling of 85 AML patients using the Olink Target 48 platform
  • T-test to compare cytokine expression between responders and non-responders
  • Elastic net regression models utilized for predicting treatment response
  • Univariate Cox regression for assessing survival risk using cytokines
  • Kaplan-Meier curves generated for survival stratification based on cytokine expression
  • The predictive model achieved 74% accuracy, increasing to 83% with additional cell population data
  • Key biomarkers identified included IL13 in responders and IL18, IL10, VEGFA, OSM, and CSF1 in non-responders
  • Cox's model linked cytokines like CSF1 and IL18 with poor survival outcomes
  • Distinct cytokine associations with response and survival were observed across different FAB types
  • TSLP, IL15, IL1B, and TNFSF12 were also among the top predictors for treatment response.

Cite This Study

Srivastava et al. (2026) studied this question.

synapsesocial.com/papers/69d1fceba79560c99a0a29fdhttps://doi.org/10.1158/1538-7445.am2026-2439
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study2025 · 1 citations
  2. 2Abstract 5852: Tumor gene expression patterns affecting response to BCl-2 inhibitor venetoclax in acute myeloid leukemia2024
  3. 3Abstract 5184: Biomarker results from PEVENAZA, a randomized phase 2 study of venetoclax and azacitidine +/- pevonedistat in newly diagnosed AML patients unfit for intensive chemotherapy: Increased efficacy in a subset of patients with IDH1/2 mutations and other observations2024
  4. 4Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study2026
  5. 5Predictive Models for Long Term Survival of AML Patients Treated with Venetoclax and Azacitidine or 7+3 Based on Post Treatment Events and Responses: Retrospective Cohort Study2024 · 9 citations